Cash Balance: Ended the year with $754 million in cash. Operating Expenses: 35% reduction in pro forma operating expenses year over year. 2026 Cash Operating Expenses: Expected to be under $390 ...

Management characterizes the current phase as an 'inflection point' where the focus shifts from building AI models to translating them into tangible clinical evidence and measurable impact.

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2025 Earnings Call Transcript February 25, 2026 Recursion Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.20528, expectations ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Good morning, everyone, and thank you so much for joining us. I want to start by briefly framing where Recursion is today and its journey and evolution. Over the past decade, Recursion has built ...

Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, showcasing a significant beat on both earnings and revenue forecasts. The company reported an EPS of -$0.21, surpassing the ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Recursion Pharmaceuticals’ latest earnings call struck a cautiously optimistic tone as management highlighted its first AI-enabled clinical proof-of-concept, major cost cuts, and an extended cash ...